Skip to main content

Table 3 Mean cerebrospinal fluid levels of bound and unbound amyloid-beta (Aβ)40 and Aβ42 in Alzheimer’s disease patients treated with solanezumab

From: Targeting the proper amyloid-beta neuronal toxins: a path forward for Alzheimer’s disease immunotherapeutics

Solanezumab dosea

Mean CSF Aβ40, pg/mLb

Mean CSF Aβ42, pg/mLb

100 mg Q4W

625

0.0

100 mg QW

3,750

275

400 mg Q4W

5,625

233

400 mg QW

15,000

825

  1. aSolanezumab phase 2 MAD data [183]. bMean pg/mL levels of total bound and unbound Aβ40 and Aβ42 in cerebrospinal fluid (CSF) of treated patients, derived from Figures 3A and 3B reported by Farlow and colleagues [183]. Q4W, monthly dosing; QW, weekly dosing.